Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Executive Summary
Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April
You may also be interested in...
Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales
Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results
Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales
Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results
Pharmacia returns apomorphine
Nastech is searching for intranasal apomorphine partner following its reacquisition of rights to the Phase II erectile dysfunction drug from Pharmacia as a condition of the Pfizer merger. Pharmacia will reimburse Nastech $13.5 mil. to terminate the deal, and is helping to retain a contract research organization. The companies signed a licensing agreement in February 2002 (1"The Pink Sheet" Feb. 11, 2002, p. 20). Pfizer markets a potential competitor, Viagra (sildenafil). The announcement indicates that the Pfizer/Pharmacia merger is progressing; the deal is expected to close in the first quarter...